Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-04-14
2009-10-27
Chang, Celia (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S326000, C546S189000, C546S193000, C546S208000, C546S209000, C546S210000
Reexamination Certificate
active
07608629
ABSTRACT:
The present invention relates to compounds of formula 1: and pharmaceutically acceptable acid addition sails thereof. The compounds of the present invention are useful for activating 5-HT1Freceptors, inhibiting neuronal protein extravasation, and for the treatment or preverition of migraine in mammals, particularly humans.
REFERENCES:
patent: 4110459 (1978-08-01), Helsley et al.
patent: 5118689 (1992-06-01), Oinuma et al.
patent: 5254689 (1993-10-01), Butera et al.
patent: 5286866 (1994-02-01), Carr et al.
patent: 5521196 (1996-05-01), Audia et al.
patent: 5521197 (1996-05-01), Audia
patent: 5708008 (1998-01-01), Audia et al.
patent: 5708187 (1998-01-01), Flaugh et al.
patent: 5721252 (1998-02-01), Audia et al.
patent: 5814653 (1998-09-01), Flaugh et al.
patent: 5942536 (1999-08-01), Fritz et al.
patent: 5962474 (1999-10-01), Audia et al.
patent: 5965562 (1999-10-01), Ofner et al.
patent: 6001849 (1999-12-01), Elliott et al.
patent: 6133290 (2000-10-01), Krushinski et al.
patent: 6358972 (2002-03-01), Filla et al.
patent: 6878714 (2005-04-01), Askew et al.
patent: 7105682 (2006-09-01), Chen et al.
patent: 705851 (1996-04-01), None
patent: A-33174/95 (1996-04-01), None
patent: 0 733 628 (1996-09-01), None
patent: 0 832 650 (1998-04-01), None
patent: 0 832 650 (1998-04-01), None
patent: WO 95 00131 (1995-01-01), None
patent: WO 96 29075 (1996-09-01), None
patent: WO-97/08144 (1997-03-01), None
patent: WO 97 13512 (1997-04-01), None
patent: WO 97/08144 (1997-06-01), None
patent: WO 98 08502 (1998-03-01), None
patent: WO 98 15545 (1998-04-01), None
patent: WO 98 20875 (1998-05-01), None
patent: WO 98 46570 (1998-10-01), None
patent: WO 98 55115 (1998-12-01), None
patent: WO 99 25348 (1999-05-01), None
patent: WO 00 00490 (2000-01-01), None
patent: WO 00 34266 (2000-06-01), None
patent: WO 00 47559 (2000-08-01), None
patent: WO 00 50426 (2000-08-01), None
patent: WO 00/00487 (2000-10-01), None
patent: WO 03/084949 (2003-10-01), None
patent: WO 2004/094380 (2004-04-01), None
Phebus et al. “Characterization of LY344864 . . . ” CA 128:18603 (1997).
Pruecher et al. “Preparation of 3-aryl . . . ” CA 122:265361 (1995).
Gaster et al. “Preparation of arylacetamide . . . ” CA 130:13850 (1998).
Cohen et al. “5-hydroxytryptamine1F . . . ” CA 131:266942 (1999).
Chen et al. “Preparation fo substituted2-(1H-indazol . . . ”CA 137:216945 (2002).
Eriksson et al. “Preparation of 5-substituted imidazolidine . . . ” CA 137:247696 (2002).
Askew et al. “Preparation of 2-aminopyridine . . . ” CA 140:16647 (2003).
King “Bioisosteres, conformational . . . ” Med. Chem. Principle and Practice. p. 206-208 (1994).
Wainscott et al. “Human 5-HT1F receptor stimulated . . . ” European J. Pharm. 352 p. 117-124 (1998).
Blanco et al. “Preparation of N-piperidinyloxy . . . ” CA 141:395422 (2004); and sample structure delineation.
Blanco et al. “Novel stubstituted N-3-1-methyl-piperidinyl . . . ” CASPLUS AN 2004:226622 (2004).
Migraine National headache foundation (2009) (one page from internet).
MayoClinic “migraine” (2009) (twelve pages from internet).
Widipedia “headache” (2009) (six pages from internet).
Parsons et al. “the neuronal verss vascular hypothesis of migraine . . . ” Curr. Opin. Pharm. v.3, p. 73-77 (2003).
Adham N et al: “Cloning of Another Human Serotonin Receptor (5-HT1F): A Fifth 5-HT1Receptor Subtype Coupled to the Inhibition of Adenylate Cyclase” Proceedings of the National Academy of Sciences of USA,US. National Academy of Science. Washington, vol. 9, No. 2, 408-412, (1993).
Johnson K, “5-HT1Freceptor agonists inhibit neurogenic dural inflammation in guinea pigs”NeuroReport8, 2237-2240 (1997).
Streitwiser, et al, “Introduction to Organic Chemistry” MacMillian Publishing Co. Inc., 586-587 (1976).
Graham, et al, “Mechanism of Migraine Headache and Action of Ergotamine Tartrate”Archives of Neurol. Psychiatry, 39:737-63, (1938).
Humphrey, et al., “Serotonin and Migraine”Ann. NY Acad. Sci., 600:587-600, (1900).
Moskowitz, M, “Interpreting vessel diameter changes in vascular headaches” Cephalalgia, 12:5-7, (1992).
Moskowitz, A. “Neurogenic inflammation in the pathophysiology and treatment of migraine”Neurology, 43 (suppl. 3) :S16-S20 (1993).
Johnson, K, et al. “A fluorescence-based method for assessing dural protein extravasation induced by trigeminal ganglion stimulation”.Neurosciences Methods81, 19-24 (1998).
Benesh Dana Rae
Blanco-Pillado Maria-Jesus
Filla Sandra Ann
Hudziak Kevin John
Kohlman Daniel Timothy
Chang Celia
Eli Lilly and Company
Tucker R. Craig
LandOfFree
(Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl,... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl,..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and (Piperidinyloxy)phenyl, (piperidinyloxy)pyridinyl,... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4097516